RANI - NASDAQ

Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc.

RANIยทNASDAQ

$0.88

+2.9%
HealthcareBiotechnology

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$57.16M
EPS-0.4500
P/E Ratio-1.94
Earnings Date08/06/2026
Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. Fair Value Envelope

RANI ยท NASDAQ

Our analysis suggests that RANI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $0.8751, this represents a potential HIDDEN relative to our calculated worth for Rani Therapeutics Holdings, Inc..

HIDDEN
Intrinsic Value
Current Price: $0.8751

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.5B
+ Cash & Equivalents$18.6M
Firm Value-$1.5B
- Debt$4.3M
Equity Value-$1.5B
/ Shares Outstanding72,992,780B
DCF Value-$20
OVERVALUED BY 2432%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$27.6M
-$40.7M
-$60.0M
-$88.4M
-$130.3M
-$192.1M
-$283.3M
-$417.6M
-$615.7M
-$907.7M
Maintenance CapEx
-$25.9K
-$38.3K
-$56.4K
-$83.1K
-$122.6K
-$180.7K
-$266.4K
-$392.8K
-$579.1K
-$853.7K
Owner Earnings
-$27.6M
-$40.7M
-$60.0M
-$88.5M
-$130.5M
-$192.3M
-$283.5M
-$418.0M
-$616.3M
-$908.6M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$25.6M
-$34.9M
-$47.6M
-$65.0M
-$88.8M
-$121.2M
-$165.4M
-$225.8M
-$308.3M
-$420.8M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your RANI research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.